Katie Wright, Author at European Medical Journal - Page 12 of 45

EAACI 2025: Oral Nut Immunotherapy Leads to Lasting Tolerance

These findings suggest that most children can maintain tolerance to nuts even after a short period without exposure, following a structured course of N-OIT.

Breakthrough Blood Test Detects Coeliac Disease Without Gluten

A novel blood-based assay could transform coeliac disease diagnosis, particularly for patients already on a gluten-free diet.

EAACI 2025: Chronic Urticaria Linked to Higher Rates of Comorbid Diseases

Conducted across 19 countries, this large-scale observational study gathered data from 1,392 patients with CSU and 1,374 healthy controls.

Onradivir Rivals Oseltamivir in Treating Influenza A

A large Phase III trial has found that onradivir, a novel PB2 polymerase inhibitor, significantly shortens recovery time in adults with uncomplicated influenza A.

Ultrasound Enhances Diagnosis of Forearm Lacerations in Trauma Care

High-resolution ultrasound improves diagnosis of tendon and nerve injuries in forearm lacerations, supporting better trauma care outcomes.

Dapagliflozin Emerges as Potential MASH Therapy in Landmark Study

Dapagliflozin shows promise for treating MASH, improving liver outcomes without worsening fibrosis in a major trial.

Diabetes Weight Loss Drugs May Double Risk of Macular Degeneration

GLP-1 RAs may significantly increase the risk of neovascular age-related macular degeneration in older adults with diabetes.

Patient-Led Weight Maintenance Outperforms Professional Care in 18-Month Trial

A new patient-led weight maintenance programme outperforms standard care, offering scalable, effective obesity management.

National Study Reveals Gaps in Paediatric Hepatitis C Treatment

These figures indicate a substantial drop-off following diagnosis, undermining efforts to eliminate HCV in paediatric populations.

Is Short-Course Tuberculosis Treatment Ready for Practice?

Participants were randomised to receive either the WHO-recommended 24-week standard regimen or one of four novel 8-week regimens.